Landmark analyses at 60 months showed a higher rate of OS for patients with high radiomics scores, which demonstrated that higher expression levels of CCR5 are linked to better prognosis in patients with ovarian cancer (p < 0.05). Here, CCR5 is linked to ovarian cancer.